OKYO Pharma Limited has filed for Fast Track designation with the U.S. FDA for its drug urcosimod, aimed at treating neuropathic corneal pain, a painful eye condition currently lacking an FDA-approved ...
Urcosimod is currently being evaluated in a phase 2 trial evaluating it's efficacy and safety in adults with neuropathic corneal pain. OKYO Pharma has filed a Fast Track designation application with ...
June 7 (UPI) --China has agreed to fast-track approvals for the shipment of rare earth minerals to the United States and some European Union nations. U.S. President Donald Trump and Chinese leader Xi ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results